People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Allena Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $80.5M | $75.0M | 2022 |
Mark C. Fitzpatrick at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark C. Fitzpatrick on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Topper | 1 | 12 |
| Robert Tepper | 1 | 7 |
| Stephen Kraus | 1 | 7 |
| Axel Bolte | 1 | 6 |
| Gino Santini | 1 | 5 |
| Alexey Margolin | 1 | 3 |
| Ann C. Miller | 1 | 2 |
| Louis Brenner | 1 | 2 |
| Gino D. Santini | 1 | 1 |
| Allene D. Diaz | 1 | 1 |
| Louis Brenner, M.D. | 1 | 1 |
| Alexey D. Margolin | 1 | 1 |
| Richard D. Katz, M.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.